# Protein kinase C in melanoma

# Table 2. (Continued)

|Cell line|PKC isoform|BI/ BII|1/t|Detection|Reference| |
|---|---|---|---|---|---|---|
|WMIIS (primary)|ND|ND|ND|ND|[36]| |
|WMIZOSLu (metastatic)|ND|ND|ND|~ %|[36]| |
|SK-Mel 28 (metastatic)|+|+|+|ND|[29]| |
|A375 (primary)| | | | |[29]| |
|Murine|:|3|ND|8| | |
|Bl6 (metastatic)|L|ND| |1|[37]| |
|Bl6-Fl (metastatic)|ND| | | |[38]| |
|BI6 (metastatic)|[|+| | |[30]| |
|B16 (metastatic)|ND|ND|ND| |[40]| |
|5S| |+|+|+|6| |
|Bl6 (metastatic)|ND|N|ND|N|3| |
| |N|ND|ND|ND|+|[44]|
|Bl6-BL6 (metastatic)| |ND| | |[45]| |
|Bl6-BL6 (metastatic)| |ND|ND|ND|[46]| |

N: Northern blot, F: Flow cytometry; W: Western blot, R: Reverse transcription-polymerase chain reaction. Not determined.

the B isoform in melanocytes [49], and further showed that PKC inhibitor reduces pigmentation in murine suggesting the involvement of the a isoform in melanogenesis skin in vivo [50]. It is interesting to assume that the B isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC B isoform [25,27]. On the other hand, the & isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,39], and the induction as well as the overexpression of this.

# Table 3. The expression of PKC isoforms in human melanoma cells in vivo

|Origin|Clinical type*|PKC isoform|BI/ BII|1/1 Detection-â‚Š|Reference|
|---|---|---|---|---|---|
|Primary|ALM|+|ND***|ND|[25]|
|Metastatic|Unknown|~|882|ND|[25]|
|Metastatic|NS (5 cases)|+|ND|ND|[27]|
|Metastatic|NS (5 cases)| |ND|ND|[27]|
|Metastatic|SSM|+|+|+|[28]|
|Metastatic|NS (5 cases)| | | |[28]|
|Metastatic|ALM (2 cases)|+|+|+|[28]|
|Primary|ALM|ND|ND|ND|[36]|
|Primary|ALM (11 cases)|+| |ND|[36]|
|Primary|SSM (cases)|+|ND|ND|[36]|
|Metastatic|ALM (2 cases)|+|ND|ND|[36]|
|Metastatic|SSM (cases)|ND|ND|ND|[36]|

#ALM: acral lentiginous melanoma; SSM: superficial spreading melanoma; NS: not stated.

24W: Western blot; immunohistochemistry. Not determined: